WHWK Aadi Bioscience: Earnings per share for the trailing year
Aadi Bioscience Inc (WHWK) is developing high-precision cancer therapy using nab-sirolimus nanoparticles to combat rare neoplasms via targeted delivery into mutated cells. The price indicator on this chart confirms the profit dynamics, which currently stand at -825.60. The business model's revenues rely on the sale of certified drugs and platform development. Operational stability in the US is guaranteed by the humanitarian status of medicine, which eliminates the impact of trade conflicts.
%20Aadi%20Bioscience&width=1200&height=400&colorIndex=0&v=mwhdatcg.m7-7dqbc3k&start=20220704&end=20261115&filename=GURU_Markets_-_WHWK_-_Aadi-Bioscience-Inc_-_Net-earnings-per-share-EPS-TTM "WHWK (Aadi Bio) Net earnings per one share for the last twelve months history from 11/23/2025 to 11/15/2026 | 👁️GURU.Markets👁️")
Aadi Bioscience, Inc. - analytical breakdowns and key metrics (WHWK)
- current quotes and average value forecast:
- company stock capitalization data:
- issuer book value statistics:
- company total debt and liquidity indicators:
Total Debt to Capital Aadi Bioscience Inc|WHWK - Long-Term Debt to Capital|Short-Term Debt to Capital Ratio aadibio.com|WHWK - Company Aggregate Debts|Debts to Net Assets Aadi Bioscience|WHWK - Company Long-Term Liabilities|Company Short-Term Loans and Borrowings Aadi Bioscience|Quick Liquidity aadibio.com
- net income and valuation ratios data:
WHWK - Net Profit|Company Profit Forecast Aadi Bioscience Inc|WHWK - Price to Earnings Ratio|Projected Price to Earnings Ratio Aadi Bioscience|WHWK - Price/Earnings to Growth Ratio|Total Company Value to Operating Income Before Depreciation Ratio Aadi Bio|WHWK - Operating profit EBITDA|Net earnings per share for the last 12 months Aadi Bioscience|WHWK - Net earnings per share (EPS TTM)|Year-over-year net earnings per share change for the last twelve months aadibio.com|WHWK - Earnings growth in current year|Expected net earnings per share growth next year Aadi Bioscience Inc
- sales and revenue indicators:
Fundamental company valuation:WHWK (Aadi Bioscience Inc)
This indicator measures the year-over-year dynamics of net earnings per share, allowing for an assessment of business monetization efficiency and the pace of capital scaling. By analyzing the historical EPS YoY growth over the last 12 months, an investor can see the impact of high margins from sarcoma target therapy and patent protection, which ensure a steady cash flow due to the monopoly position of Aadi Bioscience Inc (WHWK).
Direct competitors
Earnings per share for the trailing year ONC (BeiGene)|Halozyme Inc. (HALO) - Earnings per share for the last twelve months|RevMed - Earnings per share for the trailing year|AAPG (Ascentage Pharma Group International) - Net earnings per share (EPS TTM)|Net earnings per one share for the last twelve months CG Oncology, Inc. CGON|Net earnings per share for the last 12 months URGN (urogen.com)|Earnings per share for the last twelve months BCAX (Bicara Therapeutics)|Net earnings per share (EPS TTM) PSNL (personalis.com)|Earnings per share for the trailing year ERAS|DCTH - Earnings per share for the last twelve months|Y-mAbs Therapeutics (YMAB) - Net earnings per share for the last 12 months|AURA: Net earnings per share (EPS TTM)|Earnings per share for the last 12 months CADL|Earnings per share for the last twelve months Accuray Inc.|SELLAS Life Sciences Group (SLS) - Net earnings per share for the last four quarters|Net earnings per share for the last 12 months ACTU (Actuate Therapeutics, Inc)|Net earnings per share for the last four quarters Citius Oncology|TuHURA Biosciences, Inc. - Net earnings per share for the last 12 months|Net earnings per share (EPS TTM) Protara TARA|fatetherapeutics.com - Net earnings per share (EPS TTM)|Earnings per share for the trailing year TCRX (tscan.com)|Champions Oncology (CSBR) - Earnings per share for the last twelve months|XBiotech Inc - Earnings per share for the trailing year|Earnings per share for the last twelve months cel-sci.com|OS Therapies (OSTX) - Net earnings per share for the last four quarters|Net earnings per share for the last 12 months RADX (Radiopharm Theranostics Limited)|Earnings per share for the last four quarters ARTV|Adlai Nortye Ltd. - Net earnings per share for the last 12 months|Earnings per share for the trailing year VERU|tempesttx.com - Net earnings per share (EPS TTM)|XLO - Net earnings per share (EPS TTM)|Enochian BioSciences (RENB) - Earnings per share for the last twelve months|Net earnings per one share for the last twelve months Mural Oncology plc (MURA)|Earnings per share for the last twelve months Kairos Pharma Ltd|Net earnings per share (EPS TTM) OnKure Therapeutics|Net earnings per share for the last 12 months GDTC (w2.cytomed.sg)|Net earnings per share (EPS TTM) Curis Inc. (CRIS)|Earnings per share for the last twelve months Apollomics Inc. APLM|Earnings per share for the trailing year THAR|ADVB - Earnings per share for the last twelve months|GNPX - Net earnings per share (EPS TTM)|CLDI (calidibio.com) - Net earnings per share for the last 12 months|SBFM - Net earnings per share for the last four quarters|Net earnings per share for the last 12 months XBIO|Salarius (SLRX) - Net earnings per share for the last four quarters|Earnings per share for the last twelve months Purple Biotech Ltd. (PPBT)|Earnings per share for the last four quarters AONC|Earnings per share for the last twelve months BeiGene BGNE|CKPT - Net earnings per share for the last 12 months|elevationoncology.com - Net earnings per share (EPS TTM)|Earnings per share for the trailing year ICAD (icadmed.com)|IKNA: Net earnings per share (EPS TTM)|Earnings per share for the last 12 months NTBL|VIRX (viracta.com) - Net earnings per share (EPS TTM)|Net earnings per one share for the last twelve months MorphoSys Inc MOR|Earnings per share for the last twelve months NAYA Bio (NAYA)|AAPGV: Earnings per one share for the last 12 months
